I-CBP112

bromodomain inhibitor

Also Known As:

1-(7-(3,4-Dimethoxyphenyl)-9-(((3S)-1-methyl-3-piperidinyl)methoxy)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl)-1-propanone; 1-Propanone, 1-(7-(3,4-dimethoxyphenyl)-2,3-dihydro-9-(((3S)-1-methyl-3-piperidinyl)methoxy)-1,4-benzoxazepin-4(5H)-yl)-

Networked: 6 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - I-CBP112: 6
  - Azepines: 11
    - Oxazepines: 5
      - I-CBP112: 6

Experts

1.	Cole, Philip A: 2 articles (01/2019 - 12/2016)
2.	Zucconi, Beth E: 2 articles (01/2019 - 12/2016)
3.	Gronkowska, Karolina: 1 article (09/2021)
4.	Michlewska, Sylwia: 1 article (09/2021)
5.	Robaszkiewicz, Agnieszka: 1 article (09/2021)
6.	Strachowska, Magdalena: 1 article (09/2021)
7.	Idrees, Muhammad: 1 article (08/2019)
8.	Joo, Myeong-Don: 1 article (08/2019)
9.	Kong, Il-Keun: 1 article (08/2019)
10.	Lee, Kyeong-Lim: 1 article (08/2019)

Related Diseases

1.	Triple Negative Breast Neoplasms 12/01/2023 - "Using clinically-relevant resistant models of triple negative breast cancer (MDA-MB-231; TNBC) as well as non-small cell lung cancer (A549; NSCLC), we tested the efficacy of I-CBP112 - CBP/EP300 bromodomain inhibitor to overcome drug resistance by declining ABC gene transcription. " 09/14/2021 - "We aimed to determine if I-CBP112, which is a CBP/p300 bromodomain inhibitor, altered the vulnerability of the MDA-MB-231 cell line to chemotherapy drugs, which are used in neoadjuvant therapy in patients with triple negative breast cancer (TNBC). "
2.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/01/2023 - "Using clinically-relevant resistant models of triple negative breast cancer (MDA-MB-231; TNBC) as well as non-small cell lung cancer (A549; NSCLC), we tested the efficacy of I-CBP112 - CBP/EP300 bromodomain inhibitor to overcome drug resistance by declining ABC gene transcription. "
3.	Neoplasms (Cancer) 12/01/2023 - "Importantly, I-CBP112 treated cancer cells polarized human macrophages into proinflammatory phenotypes. " 09/14/2021 - "The inhibition of this demethylase in the presence of I-CBP112 prevented the repression of ABCC1 and ABCC10 and, to a considerable extent, cancer cells' sensitization to drugs. " 09/14/2021 - "In conclusion, the CBP/p300 bromodomain inhibitor I-CBP112 can be considered as a potent anti-multidrug-resistance agent, capable of repressing key ABC transporters responsible for drug efflux in various cancer types." 12/01/2015 - "The synergistic effects of I-CBP112 and current standard therapy (doxorubicin) as well as emerging treatment strategies (BET inhibition) provide new opportunities for combinatorial treatment of leukemia and potentially other cancers."
4.	Prostatic Neoplasms (Prostate Cancer) 01/01/2019 - "Here we show that the combination of I-CBP112 and A-485 can synergize to inhibit prostate cancer cell proliferation. " 12/01/2016 - "In addition, we show that I-CBP112 enhances H3K18 acetylation in acute leukemia and prostate cancer cells in a concentration range commensurate with its antiproliferative effects. "
5.	Leukemia 12/01/2016 - "In addition, we show that I-CBP112 enhances H3K18 acetylation in acute leukemia and prostate cancer cells in a concentration range commensurate with its antiproliferative effects. " 12/01/2015 - "I-CBP112 significantly reduced the leukemia-initiating potential of MLL-AF9(+) acute myeloid leukemia cells in a dose-dependent manner in vitro and in vivo. " 12/01/2015 - "The synergistic effects of I-CBP112 and current standard therapy (doxorubicin) as well as emerging treatment strategies (BET inhibition) provide new opportunities for combinatorial treatment of leukemia and potentially other cancers."

Related Drugs and Biologics

1.	ATP-Binding Cassette Transporters (ABC Transporters)
2.	Niacinamide (Nicotinamide)
3.	Doxorubicin (Adriamycin)
4.	polydatin

Related Therapies and Procedures

1.	Neoadjuvant Therapy
2.	Therapeutics
3.	Drug Therapy (Chemotherapy)